Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
September 23, 2025
Previous PostFDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Next PostNew Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
